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Aims. Genes of the 5-lipoxygenase pathway are compelling candidates for atherosclerosis. We hypothesize that polymorphisms
in ALOX12, ALOX15, ALOX5,a n dALOX5AP genes are associated with subclinical atherosclerosis in multiple vascular beds.
Methods. Families with two or more siblings with type 2 diabetes and their nondiabetic siblings were studied as part of the
Diabetes Heart Study (DHS). European American diabetic (n = 828) and nondiabetic (n = 170) siblings were genotyped for
SNPs in the ALOX12, ALOX15, ALOX5,a n dALOX5AP genes. Subclinical measures of atherosclerosis (IMT, coronary (CorCP),
carotid (CarCP) and aortic (AorCP) calciﬁed plaque) were obtained. Results. Associations were observed between ALOX12 with
CorCP, ALOX5 with CorCP, AorCP, and IMT, and ALOX5AP with CorCP and CarCP, independent of known epidemiologic risk
factors. Further, lipoxygenase pathway SNPs that were associated with measures of atherosclerosis were associated with markers of
inﬂammation (CRP, ICAM-1) and calciﬁcation (MGP). Conclusions. Polymorphisms within ALOX12, ALOX5,a n dALOX5AP are
genetically associated with subclinical atherosclerosis and with biomarkers of disease in families with type 2 diabetes. These results
suggest that variants in lipoxygenase pathway genes may have pleiotropic eﬀects on multiple components that determine risk of
cardiovascular disease.
1.Introduction
Atherosclerosis is thought to be the result of chronic
inﬂammation of the artery wall although the pathways
and factors that initiate and modulate the inﬂammatory
response in atherosclerosis have yet to be completely
resolved [1]. Metabolites of arachidonic acid are strong
candidates that are recognized for their inﬂammatory prop-
erties. The mouse 5-LO gene, ALOX5, has been shown
to contribute to the development of atherosclerosis [2].
Variants in the human homologue (ALOX5) are associated
with carotid artery intima-media thickness (IMT) [3].
FLAP (5-lipoxygenase activating protein), encoded by the
ALOX5AP gene, likely acts as an arachidonic acid-binding2 Mediators of Inﬂammation
and transfer protein to facilitate 5LO activity [4]. Single
SNPs and haplotypes of ALOX5AP have been associated
with myocardial infarction in multiple populations [5–
7].
Human 12-lipoxygenase (encoded by ALOX12) and 15-
lipoxygenase (encoded by ALOX15) have been localized to
atherosclerotic plaques, suggesting that 12/15LO activity
is involved in the development of atherosclerosis [8–10].
Overexpressionofhuman15-LOinmousevascularendothe-
lial cells increased markers of atherosclerosis [11]. Human
aortic endothelial cells cultured in chronically high glucose
levels results in elevated levels of 12S-HETE, suggesting
activation of lipoxygenase pathways [12, 13].
The current research was motivated by the role of
lipoxygenase pathway gene products in inﬂammation, initia-
tion/progression of atherosclerosis, and their modulation of
expression by glucose. The ALOX12, ALOX15, ALOX5, and
ALOX5AP genes represent strong candidates for atheroscle-
rosisrisk,especiallyinthecontextoftype2diabetes.Wehave
assessed genetic variants (SNPs) in lipoxygenase pathway
genes for evidence of association with markers of subclinical
atherosclerosis (intima-media wall thickness [IMT], carotid
artery calciﬁed plaque [CarCP], coronary artery calciﬁed
plaque [CorCP], and aortic calciﬁed plaque [AorCP]) and
biomarkers (e.g., ICAM-1, E-selectin, CRP) in participants
of the Diabetes Heart Study (DHS).
2. Patientsand Methods
2.1. Participants. Recruitment and phenotyping of Dia-
betes Heart Study (DHS) participants have been previously
described [14–16]. Siblings concordant for type 2 diabetes
were recruited if they had no evidence of renal insuﬃciency,
as were all available nondiabetic siblings. Participant exam-
inations were conducted in the General Clinical Research
Center of the Wake Forest University School of Medicine,
and included interviews for medical history, medication use
andhealthbehaviors,anthropometry,restingbloodpressure,
a fasting blood sampling, and a spot urine collection. Only
Caucasian participants were included in this report, due to
smallsamplesizeandlimitedstatisticalpowerintheAfrican-
American cohort. All study protocols were approved by the
Institutional Review Board of Wake Forest University School
of Medicine. All participants provided written informed
consent.
2.2. Measurements. Intima-media thickness (IMT) of the
common carotid artery was measured by high-resolution
B-mode ultrasonography with a 7.5-MHz transducer and
a Biosound Esaote (AU5) ultrasound machine [14]. The
mean of up to 20 common carotid IMT estimates was used
as the phenotypic. Calciﬁed plaque was measured in the
carotid and coronary arteries and the aorta using single
and multidetector CT systems that employ a standardized
protocol which includes CT scanner phantom testing based
on those currently implemented in the National Heart
Lung and Blood Institute’s (NHLBI) Multiethnic Study of
Atherosclerosis (MESA) studies [15, 17].
2.3. Molecular Genetics. Total genomic DNA was puriﬁed
from whole blood samples obtained from subjects using
PUREGENE DNA isolation kit (Gentra, Inc., Minneapolis,
MN). DNA was quantitated using standardized ﬂuoromet-
ric readings on a Hoefer DyNA Quant 200 ﬂuorometer
(Hoefer Pharmacia Biotech Inc., San Francisco, CA). Each
sample was diluted to a ﬁnal concentration of 5ng/μL.
Single nucleotide polymorphisms (SNPs) were identiﬁed for
ALOX12 (17p13.1), ALOX15 (17p13.3), ALOX5 (10q11.2),
and ALOX5AP (13q12) and were chosen for genotyping in
order to provide coverage of linkage disequilibrium (LD)
blocks using the Program in Genome Applications (PGA,
University of Washington) with r2 < 0.8 and minor allele
frequency (MAF) greater than 5%. As much of the HapMap
data were not available at the time of the study, relatively few
SNPs were available for each locus that passed the selection
criteria and were suitable for the genotyping platform. All
SNP genotypes were determined using a MassARRAY SNP
genotyping system (Sequenom, Inc., San Diego, CA).
2.4. Statistical Analyses. The sample means, standard devi-
ations (SD), and medians were computed on continuous
variables, while proportions were determined for discrete
variables in those DHS participants who contributed to the
genetic analyses. Variables were transformed, when required,
to meet normality assumptions. A series of generalized
estimating equations (GEE) [18] assuming exchangeable
correlation structure and using the empirical estimate of
the variance (to adjust for familial correlation induced
by selection of related individuals in sibships) was used
for assessment of the eﬀects of diabetes status on clinical
variables.
2.5. Statistical Genetic Analyses. Allele and genotype fre-
quencies were determined with unrelated subjects (a single
member from each family) and tested for departure from
Hardy-Weinberg proportions using a chi-square test (devia-
tions with P < .001 were considered signiﬁcant). Association
between each individual SNP and each phenotype was
determined using the quantitative pedigree disequilibrium
test (QPDT) [19]. The QPDT method reduces the eﬀect
of undetected stratiﬁcation bias as transmission, rather
than frequency of speciﬁc SNP alleles, is used in esti-
mating the association between SNP and phenotype. All
association analyses were conducted with adjustment for
known epidemiologic risk factors of atherosclerosis (age,
gender, diabetes status, smoking, BMI, use of aspirin,
estrogen(womenonly),andlipid-loweringandhypertension
medications).
For any SNP that exhibited a signiﬁcant association
with an atherosclerosis phenotype, additional SNPs within
the LD block were examined (when available). QPDT SNP
haplotypes were determined using the EM algorithm. QPDT
analyses were applied to these haplotypes, adjusting for the
same risk factors as in the single SNP analyses. Genotype-
speciﬁc means, medians, and number of subjects within
each genotypic class and for each measure of atherosclerosis
were computed under a speciﬁc genetic model. Analyses ofMediators of Inﬂammation 3
biomarkers (e.g., ICAM-1, E-selectin, CRP) were performed
using the same analytic strategy.
3. Results
3.1. Patient Characteristics. DNA was collected from 998
European-American subjects from 368 families. Demo-
graphic characteristics of participants are shown in Table 1.
The age at ascertainment of diabetic cases (62.0 ± 9.3 years)
was slightly older than the nondiabetic siblings (59.5 ± 10.0
years). Duration of diabetes was 10.4 ± 7.1 years, reﬂecting
a relatively early age at onset of type 2 diabetes (∼52 years).
BMI was higher in diabetic siblings (32.4 ± 6.7kg/m2) than
in nondiabetic siblings (28.9 ± 5.2kg/m2). The nondiabetic
s u b j e c t sw e r e ,o na v e r a g e ,o v e r w e i g h t( a sd e ﬁ n e db yaB M I
between 25–29.9kg/m2) and approaching obese. There were
few diﬀerences in lipid (total cholesterol, HDL, LDL) proﬁles
between diabetic and nondiabetic subjects, although lipid
lowering agents were used more commonly in the diabetic
subjects (45.4%) than in the nondiabetic subjects (27.8%).
Current and past smoking was highly prevalent in both
diabetic (59.4%) and nondiabetic (57.4%) participants.
Cardiovascular characteristics of the DHS participants
are shown in Table 2. Prevalence of CVD and extent of
atherosclerosis (CorCP, CarCP, AorCP, IMT) varied by
location (vascular bed) and diabetes. Diabetic participants
had greater prevalence of all events/procedures (heart attack,
angina, stroke, CABG, angioplasty) than nondiabetic sib-
lings. Diabetic participants had signiﬁcantly more calciﬁed
plaque in the coronary (1425 ± 29 versus 551 ± 13, mean
± stderr), carotid (374 ± 25 versus 168 ± 35), and aorta
(3995 ± 166 versus 2342 ± 309) than nondiabetic siblings;
however, there was no signiﬁcant diﬀerence in IMT with
respect to diabetes status (0.68 ± 0.01 in diabetics, 0.64 ±
0.01 in nondiabetics).
3.2. Lipoxygenase Pathway Gene SNPs. Allele and genotype
frequencies of SNPs in ALOX12, ALOX15, ALOX5, and
ALOX5AP were assessed for deviation from Hardy-Weinberg
expectations in unrelated probands (see Supplementary
Table 1 in Supplementary Material available online at
doi:10.1155/2010/170153). No SNP exhibited signiﬁcant (P
< .001) deviation from Hardy-Weinberg equilibrium. All
SNPs were maintained in subsequent analyses. The distribu-
tion of SNPs provided coverage within the block structure
of the genes, as well as providing additional coverage (either
3  or 5 ) of the regions adjacent to the lipoxygenase pathway
genes.
3.3. Lipoxygenase Pathway Genes and Coronary Calciﬁed
Plaque (CorCP). None of the 17 tagging SNPs in the
lipoxygenase pathway genes were signiﬁcantly (P < .05)
associated with CorCP (Table 3).
In exploratory analyses, four SNPs exhibited sugges-
tive association (P < .10) with CorCP, one in ALOX12
(rs2271316, P= .061, 3  of the gene), one in ALOX5
(rs2115819, P= .090, intron 3), and two in ALOX5AP
(rs9506352, P=.097, intron 2; rs4769060, P=.073, intron
Table 1: Clinical and laboratory characteristics of Caucasian DHS
participants.
Diabetic
patients
(n = 828)
Nondiabetic
patients
(n = 170)
Age (years) 62.0 ± 9.3 59.5 ± 10.0
Female (%) 51.20% 61.80%
Diabetes duration (years) 10.4 ± 7.1
BMI (kg/m2) 32.4 ± 6.7 28.9 ± 5.2
Cholesterol (mmol/L ) 4.8 ± 1.1 5.0 ± 0.9
HDL (mmol/L) 1.1 ± 0.3 1.2 ± 0.4
LDL (mmol/L) 2.7 ± 0.8 2.9 ± 0.8
CRP (mg/L) 5.1 ± 8.3 4.1 ± 6.5
Smoking (current/past) (%) 59.40% 57.40%
Lipid lowering (%) 45.40% 27.80%
Estrogen (%, in women) 26.60% 34.80%
Aspirin (%) 57.60% 53.30%
Hypertension (%) 79.40% 46.50%
4). In ALOX12, another SNP near rs2271316 was identi-
ﬁed (rs1042357, exon 8) and was genotyped. This SNP
(rs1042357) is only 10kb from rs2271316. The association
of rs1042357 with variation in CorCP was not signiﬁcant (P
= .211) and the two-SNP haplotype was also not signiﬁcant
(P=.157). Hence, the ALOX12 marginal association was not
conﬁrmed. In ALOX5, two additional SNPs were identiﬁed
(rs1369214, intron 3; rs11239524, intron 4) and were
genotyped. These two SNPs bound the ALOX5 marginally
associated SNP (rs2115819, intron 3). The ALOX5 SNP
rs1369214 is only 360bp from rs2115819, while the ALOX5
SNP rs11239524 is ∼11kb from ALOX5 SNP rs2115819. The
association between CorCP with rs1369214 was similar in
magnitude (P=.098), while the association between CorCP
with rs11239524 was much stronger (P=.027). Two- and
three-SNP haplotypes were not more strongly associated
than either the original SNP (rs2115819 in intron 3) or the
SNP in intron 4 (rs11239524), suggesting that there may
be an eﬀect of ALOX5 on variation of CorCP in intron
4 worthy of further examination. In ALOX5AP,t w oS N P s
were identiﬁed as having a marginal eﬀect on variation in
CorCP (rs9506352 in intron 2 and rs4769060 in intron 4).
Since the distance between these two SNPs is ∼17kb, three
additional SNPs (rs4769874 in intron 3, rs9315048 in intron
3, and rs12019512 in intron 4) were genotyped in these
samples. The three SNPs were not signiﬁcantly associated
with CorCP, and analyses of two-SNP haplotypes failed
to increase evidence of association. Thus, the exploratory
genotyping and data analyses for ALOX5AP SNP did not
increase evidence of association with CorCP.
3.4. Lipoxygenase Pathway Genes and Carotid Calciﬁed Plaque
(CarCP). No SNPs in the lipoxygenase pathway genes were
signiﬁcantly (P < .05) associated with CarCP (Table 3).
In exploratory analyses, one SNP in ALOX5AP
(rs10507391, P= .085, intron 1) exhibited suggestive4 Mediators of Inﬂammation
Table 2: Prevalence of CVD (%) and mean (± SD) for atheroscle-
rosis phenotypes (CorCP, CarCP, AorCP, IMT) for Caucasian
participants in the Diabetes Heart Study (DHS).
Diabetic
patients
(n = 828)
Nondiabetic
patients
(n = 170)
Prevalent CVD
Heart attack (%) 22.10% 8.30%
Angina (%) 20.40% 8.70%
Stroke (%) 10.40% 5.40%
CABG (%) 15.60% 7.70%
Angioplasty (%) 17.10% 5.30%
Endarterectomy (%) 2.30% 2.40%
Vascular Imaging
Coronary calciﬁed plaque 1425 ± 2637 551 ± 1187
Carotid calciﬁed plaque 374 ± 726 168 ± 457
Aortic calciﬁed plaque 3995 ± 4792 2342 ± 4033
Carotid IMT (mm) 0.68 ± 0.13 0.64 ± 0.12
association (P < .10). Two tagging SNPs adjacent to
rs10507391 (rs4769055 and rs9551960) span a 7kb
region in intron 1 of ALOX5AP. Two-SNP haplotype
analyses identiﬁed the rs10507391-rs9551960 haplotype as
signiﬁcantly associated with variation in CarCP (P=.002).
The rs10507391-rs9551960-rs9506352 three-SNP haplotype
was also strongly associated with CarCP (P=.003), while
the rs4769055-rs10507391-rs9551960 haplotype was not
associated (P=374). These data suggest that the ALOX5AP
eﬀect on CarCP may reside between rs10507391 (intron 1)
and rs9506352 (intron 2). No additional genotyping of other
ALOX5AP SNPs was performed.
3.5. Lipoxygenase Pathway Genes and Aortic Calciﬁed Plaque
(AorCP). No tagging SNP in the four lipoxygenase pathway
genes were signiﬁcantly associated (P < .05) with AorCP
(Table 3).
In exploratory analyses, one ALOX5 SNP (rs2115819 in
intron 3) exhibited the strongest (P=.108) association. The
rs2115819 SNP was also associated with variation in CorCP.
Two additional SNPs near the ALOX5 rs2115819 SNP were
identiﬁed for examination. Genotyping these two adjacent
SNPs in ALOX5 (rs1369214, intron 3; rs11239524, intron 4)
failed to provide evidence of association, either in analyses
of single SNPs or two- and three-SNP haplotypes. Thus, the
marginal association with AorCP was not conﬁrmed.
3.6. Lipoxygenase Pathway Genes and Intima-Media Thickness
(IMT). None of the tagging SNPs in the lipoxygenase
pathway genes were signiﬁcantly (P < .05) associated with
IMT (Table 3).
In exploratory analyses, one ALOX5 SNP (rs3780906
in intron 6) was marginally associated (P= .090) with
IMT. Two additional ALOX5 SNPs (rs3780901 in intron 4
and rs1059696 in intron 7) were identiﬁed that were near
the ALOX5 rs3780901 SNP. These SNPs were genotyped
and tested for association. Neither bordering SNP was
signiﬁcantly associated with IMT (rs3780901, P= .871;
rs1059696, P=.746). The distance spanned in ALOX5 by
thethreeSNPswas17kb.Thetwo-SNPhaplotypeformedby
rs3780901-rs3780906 (12kb between intron 4 and intron 6)
wassigniﬁcantlyassociatedwithIMT(P=.047).Further,the
three-SNP haplotype (rs3780901-rs3780906-rs1059696) was
strongly associated with IMT (P=.019). Thus, this region in
ALOX5maybeworthyoffurtherexaminationforassociation
with IMT.
3.7. Phenotypic Eﬀect of Lipoxygenase Pathway Gene Variants
on Measures of Atherosclerosis. Genotype-speciﬁc means,
medians, and number of subjects within each genotypic
class and for each measure of subclinical atherosclerosis are
presented in Table 4. Although no statistically signiﬁcant
eﬀects were observed based upon comparisons of genotypic
means (due to large variances of measured phenotypes and
long-tailed phenotypic distributions), there were interesting
trends in comparison of genotypic medians.
For the ALOX5 rs2115819 SNP with CorCP and AorCP,
the genotype-speciﬁc means suggested an inheritance pat-
tern consistent with a dominant eﬀect of allele “1”, with the
groupmean(±SE)forthecombined(1/1and2/1)genotypes
havingsigniﬁcantlylessCorCP(1127±95)andAorCP(3026
± 183) than the 2/2 genotype (1540 ± 135 and 5318 ± 540,
resp.). The “dominant” pattern is also seen for the ALOX12
rs2271316 SNP [1/1 and 2/1 genotypes having signiﬁcantly
less CorCP (1097 ± 97) than the 2/2 genotype (1423 ±
216)] and for the ALOX5AP rs9506352 SNP [1/1 and 2/1
genotypes having signiﬁcantly less CorCP (1145 ± 87) than
the 2/2 genotype (1672 ± 465)]. However, for the ALOX5AP
rs4769060 SNP, the eﬀect on CorCP appears more consistent
with additivity, with the 1/1 genotype having least CorCP
(996 ± 114), the 2/1 genotype having medium CorCP (1244
± 132), and the 2/2 genotype having the greatest CorCP
(1404 ± 247).
For CarCP, the ALOX5AP rs10507391 SNP exhibited an
additive pattern. The 1/1 genotype had greatest CarCP (360
± 37), the 2/1 genotype had intermediate CarCP (313 ±
36), and the 2/2 genotype had the least CarCP (216 ± 43).
The eﬀect of the ALOX5 rs3780906 SNP on IMT was also
“additive,” with the 1/1 genotype having the least IMT (0.666
± 0.006), the 2/1 genotype having intermediate IMT (0.675
± 0.007), and the 2/2 genotype having the greatest IMT
(0.687 ± 0.016).
3.8. Functional Support for SNP Eﬀects. The associations
of lipoxygenase pathway gene variants (ALOX SNPs) with
measures of atherosclerosis are indirect. The potential roles
of these SNPs on mechanisms of atherosclerosis were
explored by estimating the eﬀect of each associated SNP in a
select panel of biomarkers. The biomarkers evaluated in this
population include adiponectin, leptin, ICAM-1, VCAM-1,
E-selectin IL-6, CRP, MGP, and MCP-1 (Table 5).
Four lipoxygenase pathway variants contributed to
variation in CorCP—one in ALOX5 (rs2115819), one inMediators of Inﬂammation 5
Table 3: Signiﬁcance of association tests of ALOX12, ALOX15, ALOX5,a n dALOX5AP SNPs with measures of atherosclerosis, independent
of epidemiologic risk factors.
P-values∗
Gene LD Block SNP CorCP CarCP AorCP IMT
ALOX12 rs9904779 0.308 0.853 0.533 0.874
(1 block) 1 rs2292350 0.523 0.552 0.436 0.827
rs2271316 0.061 0.839 0.555 0.683
ALOX15 rs11568061 0.654 0.334 0.142 0.415
(2 blocks) 2 rs2515889 0.628 0.413 0.371 0.245
1 rs2619112 0.872 0.117 0.425 0.296
ALOX5 1 rs745986 0.183 0.743 0.157 0.478
(8 blocks) 2 rs2115819 0.09 0.553 0.108 0.286
3 rs892691 0.67 0.192 0.74 0.849
4 rs3780906 0.603 0.203 0.541 0.09
7 rs2291427 0.114 0.964 0.423 0.336
ALOX5AP rs17244974 0.251 0.572 0.492 0.173
(5 blocks) 1 rs4769055 0.201 0.805 0.242 0.376
2 rs10507391 0.288 0.085 0.648 0.473
3 rs9551960 0.591 0.136 0.174 0.591
4 rs9506352 0.097 0.369 0.188 0.511
5 rs4769060 0.073 0.378 0.456 0.299
∗Analyses performed using the quantitative pedigree disequilibrium test (QPDT); P-values adjusted for age, gender, diabetes status, smoking status, lipid
lowering medication use, BMI, estrogen use, aspirin use, and hypertension medication use.
ALOX12 (rs2271316), and two in ALOX5AP (rs9506352 and
rs4769060). The two ALOX5AP SNPs exhibited signiﬁcant
associations with levels of adiponectin (rs9506352, P=.044;
rs4769060, P=.007), CRP (rs9506352, P=.028; rs4769060,
P=.002); and MGP (rs9506352, P=.003; rs4769060, P
= .037). Levels of MGP varied in a manner consistent
with an additive gene eﬀect, based upon the observed
genotypic means [rs9506352 GG (9.06), GA (8.08), AA
(7.64); rs4769060 AA (8.89), AG (8.41), GG (7.88)]. The
ALOX12 SNP also was associated with CRP level (P=.036),
butalsosigniﬁcantlyassociatedwithICAM-1level(P=.032)
in a recessive pattern [rs2271316 GG (295.7), GC (268.3),
CC (266.0)]. The ALOX5 SNP (rs2115819) was associated
with both CorCP and AorCP. This SNP was also associated
withICAM-1(P=.037)andE-selectin(P=.0001);however,
the genotypic means did not ﬁt a classical single gene
model, as the levels of both ICAM-1 and E-selectin for
the heterozygote (T/C) class were greater than the means
for the homozygote classes. Nonetheless, these data suggest
that lipoxygenase pathway variants that are associated with
CorCP aﬀect markers of inﬂammation (CRP, ICAM-1) as
well as arterial calciﬁcation (MGP).
One SNP in ALOX5AP (rs10507391) was associated with
CarCP in this population. The ALOX5AP SNP identiﬁed
a three-SNP haplotype (rs10507391-rs9551960-rs9506352)
that was highly associated with CarCP. Each of these three
individual SNPs was signiﬁcantly (P < .05) associated with
MGP level [rs10507391 AA (7.87), AT (8.63), TT (9.83);
rs9551960 GG (7.69), GA (8.56), AA (9.64); rs9506352 GG
(9.06), GA (8.08), AA (7.64)] as was the haplotype.
A single SNP in ALOX5 (rs3780906) was associated with
variation in IMT, with a three-SNP haplotype (rs3780901-
rs3780906-rs1059696) providing strongest evidence of asso-
ciation. No consistent pattern of association was evident
with any biomarker for the single SNP or the three-SNP
haplotype.
4. Discussion
Type 2 diabetes is a major risk factor for cardiovascular
disease (CVD), whose clinical outcomes include myocardial
infarction and ischemic stroke. The principle etiologic factor
for CVD is atherosclerosis which is thought to be the result
of a chronic inﬂammatory process within a vessel wall that
precipitates a cascade of events, from establishment of a fatty
streak lesion to plaque formation [20]. The inﬂammatory
process is triggered, in part, by oxidized lipids, including
those of the lipoxygenase pathway. Recent evidence has
demonstrated that lipoxygenases have two basic functions,
(a) membrane modiﬁcation by peroxidation and (b) lipid
mediator signaling by G protein-coupled receptors [21, 22].
In the mouse, regulation of 12/15-LO and its pathway
components (12S-HETE and 13S-HODE) in the vessel
wall modulates aortic monocyte/endothelial cell interactions
[23, 24], which are key early events in vascular inﬂam-
mation [25]. Thus, the 12/15-LO pathway primarily aﬀects
atherosclerosis through LDL oxidation. An alternative path-
way involves biosynthesis of proinﬂammatory leukotrienes
(e.g., LTB4) by 5-LO (and 5-LO-activating protein, FLAP,6 Mediators of Inﬂammation
Table 4: Genotypic means (± SD) of lipoxygenase variants in ALOX5, ALOX5AP, and ALOX12 with atherosclerosis phenotypes.
Gene SNP 1/1 1/2 2/2
CorCP
ALOX5 rs2115819 1007 ± 2088 1211 ± 2489 1540 ± 2893
181 264 454
(247) (352) (145)
ALOX12 rs2271316 1065 ± 1639 1109 ± 2299 1423 ± 3155
308 223 262
(134) (341) (208)
ALOX5AP rs9506352 1101 ± 2142 1188 ± 2416 1672 ± 3721
265 229 254
(331) (332) (64)
rs4769060 996 ± 1767 1244 ± 2565 1404 ± 3086
242 264 161
(238) (377) (130)
CarCP
ALOX5AP rs10507391 360 ± 702 313 ± 694 216 ± 405
60 71 5
(358) (368) (89)
AorCP
ALOX5 rs2115819 3208 ± 4350 2908 ± 3791 5318 ± 5563
1256 1338 3158
(188) (291) (105)
IMT
ALOX5 rs3780906 0.666 ± 0.127 0.675 ± 0.129 0.687 ± 0.139
0.649 0.654 0.645
(436) (348) (75)
∗The mean phenotypic value for each genotype (1/1, 2/1, 2/2) is provided with the median and the number of individuals (n) with each genotype included
in the analysis; numbers vary based upon those with genotypic and phenotypic data.
Table 5: Association of lipoxygenase variants in ALOX5, ALOX5AP, and ALOX12 with mean levels of biomarker phenotypes.
Gene SNP ICAM-1 CRP IL-6 E-selectin Leptin Adiponectin MCP-1 MGP
ALOX5 rs2115819 TT 269.6 0.62 4.34 47.7 15.2 11.82 460.6 8.44
TC 294.8 0.66 4.58 79.7 17.9 11.01 446.5 8.47
CC 236.4 0.64 4.16 54.2 13.6 11.05 468.9 8.53
rs3780906 GG 269.8 0.66 3.95 67.6 13.6 11.13 444.7 8.48
GA 286.7 0.65 4.77 59.6 21.2 11.53 459.5 8.54
AA 228.9 0.56 4.5 51.9 6.6 11.8 505.3 7.87
ALOX12 rs2271316 GG 295.7 0.43 3.14 58.4 25.5 12.33 439.4 8.5
(17947) GC 268.3 0.75 4.68 59.3 15.7 11.03 465.3 8.59
CC 266 0.56 4.31 67.3 13.4 11.01 429.8 8.09
ALOX5AP rs10507391 AA 272.6 0.67 4.96 57.6 20.5 11.46 450.8 7.87
(4431) AT 262.2 0.6 3.9 63.8 13 11.77 459.3 8.62
TT 290.1 0.7 4.82 77.1 15.7 9.52 459 9.83
rs9506352 GG 273.2 0.69 4.3 68.7 12.9 10.69 451.7 9.06
(13151) GA 267.4 0.55 4.32 59.8 15.4 11.93 457 8.08
AA 281 0.76 4.22 58.8 26 12.35 472.3 7.64
rs4769060 AA 290.6 0.71 4.76 70.2 12.6 9.88 466.7 8.89
(30231) AG 260.9 0.57 4.23 61.1 14.6 12.1 450.9 8.41
GG 278.1 0.74 4.4 63.2 22.6 11.75 443.7 7.88Mediators of Inﬂammation 7
which transfers arachidonate to 5-LO), providing access
to downstream leukotrienes binding to G protein-coupled
receptors. Recently, it has been shown that 5-LO pathway
components are highly expressed in arterial walls in patients
with atherosclerosis of the carotid and coronary arteries and
the aorta [26].
Leukocyte-speciﬁc expression of human 15-LO has also
been shown to reduce inﬂammation and atherosclerosis in
rabbits [27, 28], most likely due to the generation of lipoxins
from the dual action of 5-LO and 15-LO on arachidonic
acid substrate in the leukocyte [29–31]. Studies in mice
in which 15-LO was selectively expressed in endothelium
indicated that endothelial-speciﬁc overexpression of 15-LO
acceleratedprogressionofatherosclerosis[12].Oneplausible
explanation for these diﬀerences is that endothelial cells do
not possess 5-LO and are unable to directly generate lipoxins
orrelatedanti-inﬂammatoryeicosanoids.Thecellularsource
of lipoxygenase may be a critical determinant of atheroscle-
rosis; hence, lipoxygenase pathways, their components, and
their genetic determinants may be central to understand-
ing the development of human atherosclerosis and CVD
risk.
Genetic factors have long been known to modulate risk
of atherosclerosis and CVD [32, 33]. In studies enriched
with diabetic individuals or those with CVD, the genetic
contribution to variation in carotid artery IMT ranges from
42%–92% [14, 34, 35]. Signiﬁcant genetic contribution to
calciﬁed plaque has also been observed, whether in the
coronary arteries [36], the carotid arteries [37, 38], or the
aorta [39].
In the Diabetes Heart Study (DHS), variation in quanti-
tative measures of subclinical atherosclerosis (CorCP, CarCP,
AorCP, and IMT) appears to be diﬀerentially inﬂuenced
by variants in genes of the lipoxygenase pathway. SNPs in
ALOX5 are associated with variation in CorCP, AorCP, and
IMT. SNPs in ALOX5AP are associated with variation in
CorCP and CarCP, while SNPs in ALOX12 are associated
with variation in CorCP. These results are consistent with
ﬁndings that have been emerging from cellular and mouse
models of atherosclerosis. Enhanced LDL oxidation, IL12
production,andendothelial/monocyteinteractionhavebeen
observed through manipulation of 12/15-LO [11, 25, 40, 41].
In mouse genetic studies, a region on mouse chromosome 6
(the site of 5-LO) was shown to be linked to atherosclerosis
susceptibility [42, 43]. Later, it was demonstrated that the
disruption of only one 5-LO allele signiﬁcantly reduced
the extent of atherosclerotic lesions at the aortic root in
LDLR−/− mice [2].
Previously, an ALOX5 variant, deﬁned by the number
of Sp1 binding motifs in the promoter, was shown to
be associated with variation in IMT and CRP level (a
marker of chronic inﬂammation) in a healthy population
[3]. The promoter variant was also shown to interact with
dietary intake of 5-LO substrates. The study population
(Los Angeles Atherosclerosis Study), in addition to being
“healthy,” was composed of several ethnic groups (Hispanic
subjects and smokers were oversampled). The DHS, on the
other hand, consists of European-American and African-
American families with at least two diabetic siblings, making
direct comparisons diﬃcult. In addition, characterization
of variation in the ALOX5 gene was diﬀerent (number of
promoter Sp1 binding motifs versus SNPs within LD blocks
across the entire ALOX5 gene). Despite these diﬀerences in
design and genetic evaluation, both studies observed that
polymorphisms in ALOX5 were associated with variation in
measures of atherosclerosis (IMT in both studies; CorCP
and AorCP in DHS). Unlike the Los Angeles Atherosclerosis
Study, we did not detect an association between SNPs in
LD blocks of ALOX5 on ultrasensitive CRP level (data not
shown).
The mechanism for associations between genes of the
lipoxygenase pathway and subclinical atherosclerosis is not
clear, although it may involve chemotaxis and proliferation
that is induced by the eﬀects of leukotrienes B4 (LTB4)
signaling in vascular smooth muscle cells. LTB4 has been
detected in human carotid artery, atherosclerotic plaques
and is derived from the 5-LO metabolism (via ALOX5AP
and through G-coupled protein receptors) of arachidonic
acid [21, 44]. Recently, a variant of the gene encoding LTB4
hydrolase (LTA4H), a protein in the same biological pathway
as ALOX5AP has been shown to be associated with risk of
myocardialinfarction[45],furtherstrengtheningthecasefor
a role of the lipoxygenase pathway on CVD risk.
Thesedatasuggestthattheremaybediﬀerentialeﬀectsof
genesinacommonpathwayonseveralvascularbedsthrough
diverse inﬂammatory mechanisms (based upon the eﬀects
of lipoxygenase pathway SNPs on subclinical atherosclerosis
and on markers of inﬂammation (CRP, E-selectin, ICAM-1)
and aspects of calciﬁcation. Recently, serum MGP levels were
determined in 2 independent populations free of clinically
apparent cardiovascular disease [46] and an association of
circulating MGP with increasing Framingham CHD risk
score was observed, as were associations of circulating MGP
with HDL and other individual CHD risk factors. Further
characterization of genes in the lipoxygenase pathway may
provide important clues to prediction of CVD. Although
variation in these genes may be associated with risk of
atherosclerosis, they may also modulate the impact of other
atherosclerotic risk factors (e.g., lipid levels) or factors that
are independent of traditional risk factors. The current data
suggest that knowledge of the genetic proﬁle of a pathway
(and, by extension, the interaction of components of the
pathway) may improve the prediction of risk. The extent
of improvement should be greater once the multilocus
examination of the pathway components becomes feasible.
In this manner, the genetic “biological network” [47]o f
atherosclerosis may become a reality.
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